EP Patent

EP2970269B1 — 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases

Assigned to Novartis AG · Expires 2017-04-19 · 9y expired

What this patent protects

Patent listed against iptacopan-hydrochloride.

Drugs covered by this patent

Patent Metadata

Patent number
EP2970269B1
Jurisdiction
EP
Classification
—
Expires
2017-04-19
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.